CSF2 and leukemia: Indeed, using intravital imaging, we show that MIF inhibition combined with GM-CSF administration in preclinical models reduces leukemia burden and results in a striking inhibition of angiogenesis in the TME in vivo, accompanied by a shift in MΦ phenotype.